| 2018 | 2017 | 2016 | 2015 | 2014 |
Ocular Therapeutix™ to Present at Oppenheimer 25th Annual Healthcare Conference
December 02, 2014
Ocular Therapeutix™ Reports Third Quarter 2014 Financial Results
November 12, 2014
Ocular Therapeutix™ Enrolls First Patients in Phase 2b Clinical Trial for Sustained Release Travoprost for the Treatment of Glaucoma and Ocular Hypertension
November 12, 2014
Ocular Therapeutix™ Announces Top-Line Results from Phase 2 Sustained Release Dexamethasone Trial for Allergic Conjunctivitis
November 12, 2014
Ocular Therapeutix™ to Report Third Quarter 2014 Financial Results and Provide Business Updates on Wednesday, November 12, 2014
November 05, 2014
Ocular Therapeutix™ to Participate in Two Investor Conferences in November 2014
October 31, 2014
Ocular Therapeutix™ to Attend American Academy of Ophthalmology Annual Meeting in Chicago, Illinois
October 14, 2014
Ocular Therapeutix™ Completes Enrollment in Phase 3 Sustained Release Dexamethasone Trials for Post-Operative Inflammation and Pain
October 08, 2014
Ocular Therapeutix to Present at the 21st Annual NewsMakers in the Biotech Industry Investment Conference on Friday, September 26
September 16, 2014
Ocular Therapeutix to Present at Morgan Stanley 2014 Global Healthcare Conference
September 03, 2014
Ocular Therapeutix Announces Second Quarter 2014 Financial Results
August 28, 2014
Ocular Therapeutix Announces Exercise of Over-Allotment Option
August 19, 2014
Ocular Therapeutix Announces Closing of Initial Public Offering
July 30, 2014
Ocular Therapeutix Prices Initial Public Offering
July 24, 2014
Ocular Therapeutix to Present New Data on Sustained Release Drug Candidates Utilizing Proprietary Hydrogel Technology at the Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting
April 28, 2014
Novel Hydrogel Sealant and Sustained Release Drug Technology Data to be Presented at the ASCRS Annual Symposium
April 21, 2014
Ocular Therapeutix Begins Phase 3 Clinical Trial for its Sustained Release Dexamethasone
March 17, 2014
Ocular Therapeutix Secures Reimbursement Code for Insertion of Drug-eluting Intracanalicular Plugs
February 26, 2014
Duke University Eye Center Performs First Cataract Surgeries using the ReSure® Sealant
February 17, 2014
Ocular Therapeutix receives FDA approval for the ReSure® Sealant
January 10, 2014
